Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00 2022-10-07 pm EDT
134.87 USD   -3.90%
09/27Asian ADRs Move Higher in Tuesday Trading
MT
09/27BeiGene Posts $1.0 Billion in Net Losses For H1
MT
09/22Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Nomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating

08/08/2022 | 07:09am EDT


© MT Newswires 2022
All news about BEIGENE, LTD.
09/27Asian ADRs Move Higher in Tuesday Trading
MT
09/27BeiGene Posts $1.0 Billion in Net Losses For H1
MT
09/22Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/20NICE Recommends BeiGene's BRUKINSA for Patients with Waldenstrom's Macroglobulinemia wh..
AQ
09/20BeiGene Receives Positive CHMP Opinion for BRUKINSA for the Treatment of Adults with Ma..
AQ
09/20BeiGene Says UK's National Institute for Health and Care Excellence Backs Approval of L..
MT
09/20England Approves BeiGene's Lymphoma Medication
MT
09/20U.K. National Institute for Health and Care Excellence Approves BeiGene's BRUKINSA As R..
MT
09/19Chinese Biotech BeiGene's Blood Cancer Therapy Wins Recommendations in EU, UK
MT
09/19NICE Recommends BeiGene's BRUKINSA® (zanubrutinib) for Patients with Waldenström's Macr..
BU
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 400 M - -
Net income 2022 -1 605 M - -
Net cash 2022 2 898 M - -
P/E ratio 2022 -10,8x
Yield 2022 -
Capitalization 14 553 M 14 553 M -
EV / Sales 2022 8,33x
EV / Sales 2023 6,11x
Nbr of Employees 8 600
Free-Float 97,9%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 140,34 $
Average target price 271,84 $
Spread / Average Target 93,7%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-48.20%14 553
REGENERON PHARMACEUTICALS, INC.15.89%78 242
VERTEX PHARMACEUTICALS35.99%76 586
BIONTECH SE-46.65%33 422
WUXI APPTEC CO., LTD.-39.54%29 123
GENMAB A/S5.32%23 876